Rani Therapeutics Holdings (RANI) Other Non-Current Liabilities (2020 - 2021)
Rani Therapeutics Holdings' (RANI) quarterly Other Non-Current Liabilities came in at $606000.0 in Q2 2021, up 89.38% quarter-over-quarter from $320000.0 in Q4 2020.
Rani Therapeutics Holdings (RANI) Other Non-Current Liabilities (2020 - 2021) Analysis & Trends
Rani Therapeutics Holdings' Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $606000.0 for Q2 2021.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $606000.0 in Q2 2021; TTM through Jun 2021 was $606000.0, a N/A change from a year earlier, with the FY2020 full-year figure at $320000.0, changed N/A from the prior year.
- Other Non-Current Liabilities rose to $606000.0 in Q2 2021 per RANI's latest filing, from $320000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $606000.0 in Q2 2021 and bottomed at $320000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Rani Therapeutics Holdings | 160.20 Mn | 167.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 606,000.00 |
| Dec 31, 2020 | 320,000.00 |